US 12,285,432 B2
Treatment of hair loss disorders with deuterated JAK inhibitors
James V. Cassella, Essex, CT (US); and Christopher L. Brummel, Marlborough, MA (US)
Assigned to Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed by Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed on Oct. 20, 2023, as Appl. No. 18/382,307.
Application 18/382,307 is a continuation of application No. PCT/US2022/040115, filed on Aug. 11, 2022.
Claims priority of provisional application 63/232,107, filed on Aug. 11, 2021.
Prior Publication US 2024/0058345 A1, Feb. 22, 2024
Int. Cl. A61K 31/519 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 45/06 (2013.01)] 28 Claims
 
1. A method of treating a hair loss disorder in a human subject in need thereof, the method comprising orally administering to the human subject about 4 mg to about 50 mg of Compound (I) represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein:
(i) about 0.1 mg to about 200 mg of a CYP3A4 inhibitor is being co-administered to the human subject; and
(ii) no adjustment of the dosage of Compound (I), or a pharmaceutically acceptable salt thereof, is required due to the co-administering of the CYP3A4 inhibitor,
wherein the hair loss disorder is alopecia areata, alopecia totalis or alopecia universalis.